GLP-1 Before Surgery: Anesthesia, Aspiration Risk and Hold Guidance
GLP-1 before surgery guide covering anesthesia aspiration risk, delayed gastric emptying, hold guidance, liquid diet, escalation phase and symptoms.
People taking semaglutide, tirzepatide, liraglutide or another GLP-1 receptor agonist are now routinely asked about surgery, colonoscopy, endoscopy and dental anesthesia. The reason is not that GLP-1 drugs are uniquely dangerous in every procedure. The concern is more specific: these medicines can delay gastric emptying, and retained stomach contents matter during general anesthesia or deep sedation.
The guidance has also changed. In 2023, the American Society of Anesthesiologists issued consensus guidance that suggested holding daily GLP-1 drugs on the day of elective procedures and weekly GLP-1 drugs for a week before the procedure. In 2024, a multi-society clinical practice guidance moved toward individual risk assessment. Most patients can continue GLP-1 therapy before elective surgery, while patients at higher gastrointestinal risk may need a liquid diet, point-of-care gastric ultrasound, anesthesia-plan changes or a delay until symptoms improve.
This guide is informational, not medical advice. Medication decisions before anesthesia should be made by the prescribing clinician, surgeon, anesthesiology team and patient. That is especially important for people using GLP-1 medicines for diabetes, because stopping therapy can affect glucose control.
For broader drug context, see the PeptideStat guides on semaglutide, tirzepatide, GLP-1 side effects, GLP-1 dosage schedules and GLP-1 treatment planning.
Quick Answer
| Question | Evidence-aware answer |
|---|---|
| Is every GLP-1 user told to stop before surgery? | No. Current multi-society guidance says most patients can continue before elective surgery. |
| Why was there concern? | GLP-1 drugs can delay gastric emptying, and retained stomach contents can raise regurgitation and aspiration concern under anesthesia or deep sedation. |
| Who may need extra planning? | People early in dose escalation, recently increased dose, active nausea, vomiting, abdominal pain, known gastroparesis or other delayed-emptying risks. |
| What can the team do? | Use a 24-hour liquid diet for selected patients, adjust anesthesia technique, use gastric ultrasound where available or delay elective procedures in high-risk situations. |
| Should patients decide alone? | No. Tell the care team the exact drug, dose, last dose, symptoms and reason for treatment. Let the medical team set the plan. |
Why GLP-1 Drugs Matter To Anesthesia
The stomach normally empties solids and liquids in a timed pattern. Standard preoperative fasting rules are built around that physiology. GLP-1 receptor agonists change the picture because delayed gastric emptying is part of their pharmacology, especially early in treatment or during dose increases.
Delayed emptying is one reason these medicines can reduce appetite and food intake. It is also why labels for products such as Wegovy say the drug delays gastric emptying and may affect absorption of oral medications. Wegovy's current label also includes a warning that pulmonary aspiration during general anesthesia or deep sedation has been reported in patients receiving GLP-1 receptor agonists.
That does not mean every person on a GLP-1 has a full stomach. The risk is variable. Dose, time on therapy, active gastrointestinal symptoms, diabetes, other medications, other stomach-emptying disorders and procedure type can all change the practical decision.
How The Guidance Changed
The 2023 ASA consensus guidance was intentionally conservative because evidence was limited and case reports were accumulating. It suggested holding daily GLP-1 receptor agonists on the day of the procedure and weekly drugs one week before elective procedures, regardless of indication or dose.
The 2024 multi-society guidance took a different approach. It says most patients can continue GLP-1 receptor agonists before elective surgery. The document focuses on identifying patients at highest risk for delayed gastric emptying and using targeted risk-reduction steps rather than applying the same hold rule to everyone.
That shift matters. Holding a GLP-1 may reduce one theoretical anesthesia concern, but it can create other problems: worse glucose control in diabetes, loss of appetite control, insurance or refill disruptions, and confusion about restarting. The newer approach asks whether the patient is actually at higher gastric-risk at that moment.
Higher-Risk Situations
Current guidance and perioperative reviews point to several practical risk groups.
| Risk factor | Why it matters | Practical implication |
|---|---|---|
| Dose-escalation phase | GI effects are often more active while the dose is being increased | Elective procedures may be scheduled after escalation stabilizes when possible |
| Recent dose increase | Nausea, fullness or slowed emptying may intensify after a dose step | Tell the anesthesia team the date of the last dose increase |
| Active nausea or vomiting | Symptoms suggest delayed emptying or intolerance may be present | Elective cases may be delayed until symptoms improve |
| Abdominal pain, bloating or severe constipation | These may point to meaningful GI slowing or another disorder | The team may treat the patient as higher risk |
| Known gastroparesis or delayed emptying | Baseline motility is already abnormal | GLP-1 use adds to an existing concern |
| Deep sedation or general anesthesia | Airway reflexes are reduced | Aspiration risk planning becomes more important |
This is why a simple "last dose date" is not enough. The team needs symptoms, drug, dose, timing, indication and procedure context.
What To Tell The Surgical Team
Before a planned procedure, give the team concrete information:
- The exact medicine: for example Wegovy, Ozempic, Rybelsus, Zepbound, Mounjaro, Saxenda, Victoza or a compounded GLP-1.
- The active drug if you know it: semaglutide, tirzepatide or liraglutide.
- Whether it is daily, weekly or oral.
- The current dose and whether you recently increased it.
- The date and time of the last dose.
- Why you use it: diabetes, weight management, cardiovascular risk reduction, MASH or another indication.
- Any nausea, vomiting, reflux, abdominal pain, bloating, constipation or early fullness.
- Any known gastroparesis, prior aspiration, bariatric surgery or significant reflux history.
- Other medicines that slow the gut, including opioids or anticholinergic drugs, if applicable.
If the product is compounded, say so. Compounded GLP-1 products do not have the same product-specific label, device, dose schedule or FDA review as approved products. PeptideStat covers that distinction in the compounded GLP-1 guide.
Drug Examples
| Drug or product type | Usual schedule | Perioperative relevance |
|---|---|---|
| Semaglutide injection, such as Wegovy or Ozempic | Weekly | Long half-life means "holding one dose" is not the same as removing all drug effect |
| Semaglutide tablet, such as Rybelsus or oral Wegovy formats | Daily | Daily dosing raises a different scheduling question from weekly injections |
| Tirzepatide, such as Zepbound or Mounjaro | Weekly | A GLP-1/GIP dual agonist with GI effects and product labeling that should be reviewed |
| Liraglutide, such as Saxenda or Victoza | Daily | Shorter schedule than weekly agents, but still a GLP-1 receptor agonist |
| Compounded GLP-1 products | Variable | Dose, salt form, concentration and labeling can vary; tell the care team exactly what is being used |
For drug comparisons, use Ozempic vs Wegovy, Zepbound vs Wegovy and the FDA-approved GLP-1 guide.
What A Liquid Diet Does And Does Not Do
The 2024 multi-society guidance includes a 24-hour liquid-only diet as one option for patients at higher risk. The idea is practical: liquids generally empty differently from solids, and reducing solid residue may lower the chance of retained solid food.
A liquid diet is not a universal rule and not a guarantee. It should come from the surgical or anesthesia team, especially if the person has diabetes, kidney disease, pregnancy, eating-disorder history, frailty or other nutrition risks.
The plan may also include procedure timing, glucose monitoring, medication adjustment, or point-of-care gastric ultrasound if the anesthesia team has the equipment and training.
Gastric Ultrasound
Gastric ultrasound is being studied as a way to assess stomach contents near the time of anesthesia. Reviews and prospective studies describe it as a useful tool in selected GLP-1 users, but it is not available in every setting and does not replace clinical judgment.
If ultrasound shows a stomach that appears full, the team may delay the case, modify the airway plan or treat the patient as having a full stomach. If ultrasound is not available, risk assessment depends more heavily on symptoms, history, timing and procedure urgency.
If Surgery Is Urgent
Emergency procedures cannot always wait for a GLP-1 plan. In urgent cases, the anesthesia team may treat the patient as higher aspiration risk and adjust the airway or induction strategy. The patient or family should still tell the team about recent GLP-1 use, the last dose and symptoms if known.
Do not hide use because a product was bought online or compounded. The anesthesia team needs accurate information to reduce avoidable risk.
Bottom Line
GLP-1 surgery guidance is now risk-based. Most patients can continue GLP-1 medicines before elective procedures under the 2024 multi-society guidance, but that does not make the issue trivial. Delayed gastric emptying, active GI symptoms, dose escalation and deep sedation or general anesthesia can change the plan.
The most useful patient action is simple: tell the surgical and anesthesia team exactly what you take, when you last took it and how your stomach feels. The right plan may be continue, hold, liquid diet, ultrasound, delay or full-stomach precautions depending on the procedure and risk profile.
References
American Society of Anesthesiologists. New Multi-Society GLP-1 Clinical Practice Guidance Released.
American Society of Anesthesiologists. Consensus-Based Guidance on Preoperative Management of Patients on GLP-1 Receptor Agonists.
DailyMed. Wegovy semaglutide prescribing information.
DailyMed. Zepbound tirzepatide prescribing information.
Abdallah OW, et al. Peri-Procedural Fasting and Gastric Ultrasound Strategies in GLP-1 Receptor Agonist Users.
Kindel TL, et al. Perioperative management of GLP-1 receptor agonists: international guidance and variability in recommendations.
Mertz K, et al. Gastric ultrasound in patients receiving semaglutide: a prospective, multicentre, matched control study.
Han S, et al. Delayed gastric emptying induced by GLP-1 receptor agonists and its implications for perioperative risk during anesthesia.
Martinez-Palli G, et al. Perioperative bronchoaspiration in a semaglutide user on a residue-free diet: a case report and insights from a complication.
Zapp C, et al. The Risk of Aspiration Is Low With Continuing Semaglutide During Elective Eye Surgery When Patients Receive Only Moderate Sedation.